^(125)I-抗AFP抗体放射免疫导向治疗原发性肝癌的初步临床观察  

Preliminary clinical trials of 125IantiAFP antibody radioimmunity targeting therapy for hepatocellular carcinoma(HCC)

作　　者：宋向群[1] 吴英德[1] 杨克政 周德南 甘友全 

机构地区：[1]广西医科大学附属肿瘤医院

出　　处：《癌症》1999年第3期332-335,共4页Chinese Journal of Cancer

基　　金：广西科委资助

摘　　要：目的：观察１２５Ｉ抗ＡＦＰ抗体导向治疗肝癌的毒副反应、药物体内代谢及近期疗效。方法：采用氯胺Ｔ氧化法制备１２５Ⅰ抗ＡＦＰ抗体，经静脉给药，治疗２１例不能手术切除的原发性肝癌，每例接受１２５Ⅰ的中位剂量为２８９３ＭＢｑ（１００３～７０８９ＭＢｑ）。结果：药物在血浆清除缓慢，第１５天１２５Ⅰ血浓度仍为５２７５±１０５３×１０－４％。药物毒性低，耐受好。治后总有效率（ＣＲ＋ＰＲ＋ＭＲ）为４４４％（８／１８），平均生存１４２个月（４～６０个月），一年生存率为３８９％（７／１８）。结论：１２５Ｉ抗ＡＦＰ抗体治疗肝癌毒性低，耐受性好，安全，易防护，并获得较好的近期疗效。Objective: To observe biodistribution, therapeutic effects and toxicside reaction of 125IantiAFP antibody in the therapy of hepatocellular carcinoma. Methods: 21 cases of HCC were treated with 125antiAFP antibody, which was made by modified chloraminT method. Drug was administered by intravenous drip. The median dose of 125in the whole group was 3893 MBq (10037089MBq). Results: 125antiAFP antibody was cleared slowly in plasma. The blood concentration was 5275105310-4%in fifteenth day after the use of the drug. The toxicity of 125antiAFP antibody is mild and tolerable. After the treatment, overall response rate (CR+PR+MR) was 444%(8/18),average survival was 142 months (460 months).the 1year survival rate was 389%(7/18). Conclusion: The use of 125IantiAFP antibody in the treatment of HCC is effective, low toxic, safe and easily protectable, so it is worth for further studying.

关 键 词：碘125 抗AFP抗体 原发性 肝肿瘤 

分 类 号：R735.705[医药卫生—肿瘤]